Grade: Pharmaceutical Grade

Factory Location: Xiamen, Fujian

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

Monthly Production Capacity: 1000kg

Packaging Information: 25kg/drum 1kg/bottle

Delivery Lead Time: 7 days after payment

Sample Provided: yes

Payment Terms: L/L

 

Product Information

 

Product name	Ticagrelor
CAS No.	274693-27-5
Molecular Formula	C23H28F2N6O4S
Molecular Weight	522.576
Quality Standard	99% up by HPLC
Appearance	White to off-white powder

 

COA of Ticagrelor

 

ITEMS	SPECIFICATION	RESULTS
Appearance	White to off-white powder	Conforms
Optical rotation	-50。~ 60。	-53。
Identification	IR	Conforms
	HPLC	Conforms
Isomers	TGD1≤0.15%	Undetected
	TGD2≤0.15%	Undetected
	TGE≤0.15%	Undetected
	TG-16≤0.15%	Undetected
Related substance	De-ethoxyl of TG ≤ 0.15%	0.01%
	Any single impurity ≤ 0.1%	0.05%
	Total impurities ≤ 1.0%	0.10%
Residue on ignition	≤ 0.1%	0.08%
Loss on drying	≤ 0.5%	0.14%
Residual solvent	Ethyl ether <5000ppm Acetone<5000ppm Dichloromethane <600ppm Ethyl acetate <5000ppm Triethylamine <320ppm Toluene<890ppm Tetrahydrofuran <720ppm Methanol<3000ppm Ethanol<5000ppm Acetonitrile<4 10ppm hexane <290ppm N-methyl pyrrolidone<530ppm	Undetected Undetected Undetected 73 ppm Undetected Undetected Undetected Undetected Undetected Undetected Undetected Undetected
Assay	99%-102%	100.5%
Conclusion	The result conforms to the enterprise standards.

 

Usage

 

Function of Ticagrelor

Today, with the continuous increase of acute coronary syndrome (ACS), antiplatelet therapy is still one of the important treatment measures for ACS. Ticagrelor is a novel cyclopentyltriazole pyrimidine (CPTP) oral antiplatelet drug with ATC code B01AC24. Ticagrelor is a non-prodrug that can act directly without hepatic metabolic activation, and binds reversibly to the P2Y12 ADP receptor. The results of the PLATO study showed that ticagrelor treatment for 12 months, without increasing major bleeding, further significantly reduced the risk of cardiovascular death/myocardial infarction/stroke composite endpoint events in ACS patients by 16%, and significantly Reduce cardiovascular death by 21%. The clinical efficacy and safety of ticagrelor have been validated and supported by the Platelet Inhibition and Patient Outcomes Outcomes Study (PLATO Study) and its multiple subgroups. Based on the benefits of ticagrelor treatment for ACS patients, guidelines in many countries state that ticagrelor is listed as the first-line recommendation. In the two authoritative guidelines of the European Society of Cardiology (ESC NSTE-ACS guidelines in 2011 and STEMI guidelines in 2012), it is pointed out that the use of clopidogrel in patients who cannot receive ticagrelor therapy is sufficient. Shows approval for the new drug to further reduce mortality.